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P U B L I S H E D B Y E L S E V I E R I N C .LettersIntravenous Hydration
(With or Without
Rosuvastatin) Should
Remain the Cornerstone
of the Prevention of
Contrast-Induced Acute
Kidney Injury in Patients
With Diabetes and
Chronic Kidney DiseaseIn a recent randomized, controlled, multicenter trial,
Han et al. (1) showed that rosuvastatin, compared
with “standard of care,” signiﬁcantly reduced the
risk of contrast-induced acute kidney injury (AKI) in
diabetic patients with chronic kidney disease
undergoing an intra-arterial contrast medium
injection. On the basis of Figure 3, the authors claim
that rosuvastatin was consistently effective among
various subgroups. We disagree. No effect (p ¼ 0.89)
was observed in approximately 43% of patients
given intravenous hydration (the standard of care,
not given consistently in this study, in contrast to
the authors’ claim). Thus, we conclude that
rosuvastatin may at best prevent contrast-induced
AKI in some patients not given intravenous
hydration. The latter will remain the cornerstone
of the prevention of contrast-induced AKI, as
summarized by the Class I Level of Evidence: A in the
recent Kidney Disease: Improving Global Outcomes
guidelines (KDIGO) (2).Nicolas Cecere, MD
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Int 2012;2 Suppl:1–138.REPLY: Intravenous Hydration (With or
Without Rosuvastatin) Should Remain the
Cornerstone of the Prevention of Contrast-
Induced Acute Kidney Injury in Patients With
Diabetes and Chronic Kidney DiseaseWe thank Dr. Cecere and colleagues for their interest
in and comments on our study (1). They raise a very
important question of whether rosuvastatin was
consistently effective among various subgroups,
especially the subgroup of patients with or without
intravenous hydration.
We agree that intravenous hydration is an impor-
tant factor that should be well controlled in a study
in either the design or analysis phase. Unfortunately,
no special consideration (e.g., stratiﬁed randomiza-
tion) was given in the design phase back in 2008
when this preventing strategy was not yet well
established in the guidelines (2). Therefore, hydration
was administered at the discretion of individual
investigators according to their daily practice.
Is hydration a confounding factor to our conclusion?
Looking at our data, ﬁrst in Table 1 (1), we observed
that hydration therapy was well balanced across 2
arms, probably as a result of our large sample size
(44.9% and 42.8% in the rosuvastatin and control
groups, respectively), which reassured us a bit that
hydration therapy is unlikely to confound our overall
conclusion that rosuvastatin can signiﬁcantly reduce
the risk of contrast-induced acute kidney injury
(CI-AKI) in patients with diabetes mellitus (DM) and
chronic kidney disease (CKD) undergoing arterial
contrast medium injection. This was further
examined and conﬁrmed in a multivariate analysis
as shown in Table 4 (2) that hydration was not an
independent predictor of CI-AKI (odds ratio: 0.83,
95% conﬁdence interval: 0.53 to 1.31, p ¼ 0.43), and
most importantly, in a test of treatment by hydration
interaction (p > 0.05, data not shown).
